Is a double-blind clinical trial really double-blind? - A report of doctors' medication guesses

Karl Rickels, Ronald S. Lipman, Seymour Fisher, Lee C. Park, Eberhard H. Uhlenhuth

Research output: Contribution to journalArticle

Abstract

In a double-blind trial of meprobamate and placebo, carried out with 138 anxious neurotic outpatients, psychiatrists performed medication guesses after 2, 4, and 6 weeks of therapy. At the same time, physician and patient independently completed several improvement measures and the physician recorded the presence or absence of side reactions as spontaneously reported by the patient. The results may be summarized as follows: a) Clinical improvement and side effects often enable the physician to make reliable medication guesses and thus break the double-blind design in drug trials. b) Clinical improvement seems to exert the most important influence in determining physician medication guesses, at least with anti-anxiety drugs in studies of only 4 to 6 weeks duration. c) The correlation between side effects and medication guesses increases with the duration of therapy.

Original languageEnglish (US)
Pages (from-to)329-336
Number of pages8
JournalPsychopharmacologia
Volume16
Issue number4
DOIs
StatePublished - Jan 1 1970

Keywords

  • Anxiety Neurosis
  • Clinical Improvement
  • Medication Guess
  • Meprobamate
  • Side Effects

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Is a double-blind clinical trial really double-blind? - A report of doctors' medication guesses'. Together they form a unique fingerprint.

  • Cite this